Isolation and characterization of a new candidate human inactivated rotavirus vaccine strain from hospitalized children in Yunnan, China: 2010-2013

Wu, Jinyuan; Zhou, Yan; Guangming, Zhang; Mu, Guo-Fa; Yi, Shan; Yin, Na; Yuping, Xie; Lin, Xiaochen; Li, Hongjun; Sun, Maosheng

doi:10.12998/wjcc.v6.i11.426

Cited by 6 publications

(2 citation statements)

References 41 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A combined inactivated polio vaccine (IPV)–IRV product is also under development with this same strain, and has been tested in mice, with no evidence of interference of the immune response to either component [81]. Other early-stage candidates include an inactivated G1P[8] strain isolated from a hospitalized Chinese infant [82] and a truncated VP4 based on the LLR strain [83].…”

Section: Rotavirus Vaccine Pipelinementioning

confidence: 99%

Current and new rotavirus vaccines

Burke

Tate

Kirkwood

et al. 2019

Current Opinion in Infectious Diseases

147

View full text Add to dashboard Buy / Rent full text

Purpose of reviewAs of 2019, four rotavirus vaccines have been prequalified by the WHO for use worldwide. This review highlights current knowledge regarding rotavirus vaccines available, and provides a brief summary of the rotavirus vaccine pipeline.Recent findingsData generated from use of currently available products supports their effectiveness and impact in diverse settings. Rotavirus vaccines have a favorable risk–benefit profile, but previous associations of rotavirus vaccination with intussusception necessitate continued monitoring for this rare but serious adverse event. Implementation of rotavirus vaccines was jeopardized in late 2018 and 2019 by a shortage of vaccine supply. Fortunately, with the prequalification of two additional vaccines in 2018, countries have increased choice in products with different characteristics, pricing, and implementation strategies. Other vaccines currently in development may open up further immunization strategies, such as neonatal vaccination schedules or parenteral administration.SummaryRotavirus vaccines have demonstrated impact in reducing diarrheal morbidity and mortality worldwide. As countries begin to introduce the newly prequalified vaccines, additional data will become available on the safety and effectiveness of those products. Products in the pipeline have distinct profiles and could be an essential part of the expansion of rotavirus vaccine use worldwide.

show abstract

Section: Rotavirus Vaccine Pipelinementioning

confidence: 99%

Current and new rotavirus vaccines

Burke

Tate

Kirkwood

et al. 2019

Current Opinion in Infectious Diseases

147

View full text Add to dashboard Buy / Rent full text

show abstract

“…Inactivated RV vaccines (IRVV) are origin from weakened or killed RV strains like human RV strain CDC-9, G2P [8], G3P [8], G9P [8] and G1P [8] and ZTR-68 by stimulating antibodies against RV infection. [170][171][172][173][174][175][176][177][178] IRVV protected animal models through different challenging routes like oral or intramuscular, microneedle delivery for skin vaccination in preclinical trials. According to several studies, intramuscular inoculation with three doses of IRVV could elicit high serum IgG antibody and neutralizing antibody responses in gnotobiotic piglets, 171 which is similar to the results of mice model.…”

Section: Other Candidate Vaccinesmentioning

confidence: 99%

The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review

Wang

Liu

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Buy / Rent full text

Rotavirus, which causes acute gastroenteritis and severe diarrhea, has posed a great threat to children worldwide over the last 30 y. Since no specific drugs and therapies against rotavirus are available, vaccination is considered the most effective method of decreasing the morbidity and mortality related to rotavirus-associated gastroenteritis. To date, six rotavirus vaccines have been developed and licensed by local governments. Notably, Rotarix™ and RotaTeq™ have been recommended as universal agents against rotavirus infection by the World Health Organization; however, lower efficacies were found in lessdeveloped and developing regions with medium and high child mortality than well-developed ones with low child mortality. For now, two promising novel vaccines, Rotavac™ and RotaSiil™ were pre-qualified by the World Health Organization in 2018. Other rotavirus vaccines in the pipeline including neonatal strain (RV3-BB) and several non-replicating rotavirus vaccines with a parenteral delivery strategy are currently undergoing investigation, with the potential to improve the performance of, and eliminate the safety concerns associated with, previous live oral rotavirus vaccines. This paper reviews the important developments in rotavirus vaccines in the last 20 y and discusses problems and challenges that require investigation in the future.

show abstract

Isolation and characterization of a new candidate human inactivated rotavirus vaccine strain from hospitalized children in Yunnan, China: 2010-2013

Cited by 6 publications

References 41 publications

Current and new rotavirus vaccines

Current and new rotavirus vaccines

The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review

Contact Info

Product

Resources

About